SX-682

Phase 2Small molecule

SSyntrix Biosystems, Inc.

SX-682 is one of 206 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Prostate CancerActive, not recruiting

Head and Neck CancerNot yet recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Head and Neck CancerPreclinical

Not yet recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

SX-682

SSyntrix Biosystems, Inc.

Phase 2

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Pancreas Cancer

NCT05604560

Q4 2026

Phase 1Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT04477343

Q2 2027

Phase 1Active, not recruiting

Metastatic Melanoma

NCT03161431

Q2 2028

Phase 2Recruiting

Prostate Cancer

NCT06228053

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting·SSyntrix Biosystems, Inc.·Phase 2·NCT06228053·53 enrolled

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT07002320·78 enrolled

Metastatic Melanoma1 trial

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Active, not recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT03161431·77 enrolled

Advanced Solid Tumors1 trial

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT04574583·12 enrolled

Pancreas Cancer1 trial

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Active, not recruiting·LLei Zheng·Phase 2·NCT05604560·25 enrolled

Myelodysplastic Syndrome1 trial

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled

3 more indications

Head and Neck Cancer1 trial

Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07667400·120 enrolled

Metastatic Colorectal Cancer1 trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06149481·60 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·UUniversity of Rochester·Phase 1·NCT04477343·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for SX-682. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SX-682 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SX-682. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syntrix Biosystems, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyntrix Biosystems, Inc.

SX-682

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q2 2028

Trials by Indication[1]

Prostate Cancer2 trials

Metastatic Melanoma1 trial

Advanced Solid Tumors1 trial

Pancreas Cancer1 trial

Myelodysplastic Syndrome1 trial

Head and Neck Cancer1 trial

Metastatic Colorectal Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News